Of note, the presence of TP53, RB1 and PTEN alterations have previously been associated with poor patient outcomes related to TILP and the generation of an aggressive neuroendocrine or adeno-neuroendocrine tumor phenotype and39–41. This evidence concerns the gene TP53 and neuroendocrine neoplasm.